drugset / Trial / NCT01733758

A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT01733758

Phase 3 Completed 494 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in Japanese subjects with Type 2 diabetes mellitus.

Timeline

Start
2013-02
Primary completion
2014-06
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liraglutide Peptide 0.9 mg Subcutaneous
Subject albiglutide Peptide 30 mg Subcutaneous
Subject albiglutide Peptide 50 mg Subcutaneous